LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 78

Search options

  1. Article ; Online: Corrigendum to "The prophylaxis and treatment potential of supplements for COVID-19" [Eur. J. Pharmacol. 887 (15 November 2020) 173530].

    Sahebnasagh, Adeleh / Saghafi, Fatemeh / Avan, Razieh / Khoshi, Amirhosein / Khataminia, Masoud / Safdari, Mohammadreza / Habtemariam, Solomon / Ghaleno, Hassan Rezai / Nabavi, Seyed Mohammad

    European journal of pharmacology

    2024  Volume 972, Page(s) 176571

    Language English
    Publishing date 2024-04-12
    Publishing country Netherlands
    Document type Published Erratum
    ZDB-ID 80121-5
    ISSN 1879-0712 ; 0014-2999
    ISSN (online) 1879-0712
    ISSN 0014-2999
    DOI 10.1016/j.ejphar.2024.176571
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.

    Jaafarinia, Asma / Kafami, Behzad / Sahebnasagh, Adeleh / Saghafi, Fatemeh

    BMC complementary medicine and therapies

    2022  Volume 22, Issue 1, Page(s) 262

    Abstract: Background: Diabetic nephropathy (DN) is one of the most important complications of type 2 diabetes (T2DM). Oxidative stress and inflammatory cytokines play an essential role in the development and progression of DN. Despite adopting appropriate ... ...

    Abstract Background: Diabetic nephropathy (DN) is one of the most important complications of type 2 diabetes (T2DM). Oxidative stress and inflammatory cytokines play an essential role in the development and progression of DN. Despite adopting appropriate therapies, many patients with DN progress to end-stage renal disease (ESRD). Therefore, exploring innovative strategies for better management of DN is crucial. Crocin, a natural compound found in saffron, has profound antioxidant, antifibrotic and anti-inflammatory properties. This study aimed to evaluate the therapeutic effects of crocin in attenuation of the progression of DN.
    Methods: In this randomized, triple-blind, placebo-controlled clinical trial, 44 patients with T2DM and microalbuminuria were randomly assigned to receive either crocin (15 mg/day) or a placebo for 90 days. Eventually, 40 patients completed the study: 21 patients in the crocin group and 19 in the placebo group. The primary outcome was a change in urine Albumin-to-Creatinine Ratio (uACR) from baseline to the end of the treatment period. We also evaluated metabolic, anthropometric, and biochemical parameters as the secondary outcomes.
    Results: The results of the present study showed that uACR increased in both groups, but the increment was not significantly higher in the crocin group compared with the placebo. Serum levels of transforming growth factor-β (TGF-β) decreased in the crocin group and increased in the placebo group, but none of these changes was significant. Crocin significantly reduced triglyceride (TG) as an important metabolic parameter (P-Value = 0.03).
    Conclusion: This study has shown that crocin may be a safe and potential adjunct to conventional therapies for DN patients but because of our limitations such as short duration of the treatment period, and prescribing low doses of crocin, we could not achieve the significant level.
    MeSH term(s) Albumins/therapeutic use ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Carotenoids ; Creatinine ; Cytokines ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetic Nephropathies/drug therapy ; Humans ; Transforming Growth Factor beta ; Transforming Growth Factors/therapeutic use ; Triglycerides
    Chemical Substances Albumins ; Antioxidants ; Cytokines ; Transforming Growth Factor beta ; Triglycerides ; Carotenoids (36-88-4) ; Transforming Growth Factors (76057-06-2) ; crocin (877GWI46C2) ; Creatinine (AYI8EX34EU)
    Language English
    Publishing date 2022-10-08
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial
    ISSN 2662-7671
    ISSN (online) 2662-7671
    DOI 10.1186/s12906-022-03744-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Efficacy of the Novel Formulation of Topical Liothyronine and Liothyronine-Insulin in Mild to Moderate Diabetic Foot Ulcer: A Randomized, Triple-blind Clinical Trial.

    Saghafi, Fatemeh / Khalilzadeh, Saeed Hossein / Ramezani, Vahid / Pasandeh, Fatemeh / Fallahzadeh, Hossein / Sahebnasagh, Adeleh

    Current medicinal chemistry

    2023  

    Abstract: Background: Diabetic foot ulcer (DFU) is one of the challenging complications of chronic diabetes.: Objective: The study aimed to investigate whether liothyronine (T3) and liothyronine-insulin (T3/Ins) topical preparations could significantly reduce ... ...

    Abstract Background: Diabetic foot ulcer (DFU) is one of the challenging complications of chronic diabetes.
    Objective: The study aimed to investigate whether liothyronine (T3) and liothyronine-insulin (T3/Ins) topical preparations could significantly reduce the healing time of DFU.
    Methods: A prospective, randomized, placebo-controlled, patient-blinded clinical trial was conducted on patients with mild to moderate DFU, over a lesion area of no greater than 100 cm2. The patients were randomized to receive T3, T3/Ins, or honey cream 10% as the routine of care twice a day. Patients were examined for tissue healing weekly for 4 weeks, or until the total lesion clearance was observed, whichever was earlier.
    Results: Of 147 patients with DFUs, 78 patients (26 per group) completed the study and were included in the final evaluation. At the time of study termination, all participants in each of the T3 or T3/Ins groups were free of symptoms based on the REEDA score, while about 40% of participants in the control group were detected with each of grades 1, 2, or 3. A significant difference was observed on days 7, 14, and 21 of consumption of topical preparations (P-value < 0.001). The mean time to complete wound closure in the routine care group was about 60.6 days, while it was 15.9 and 16.4 days in T3 and T3/Ins groups, respectively. Within the T3 and T3/Ins groups, significant earlier wound closure was detected at day 28 (P-value < 0.001).
    Conclusion: T3 or T3/Ins topical preparations are effective for wound healing and acceleration of wound closure in mild to moderate DFUs.
    Language English
    Publishing date 2023-05-23
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 1319315-6
    ISSN 1875-533X ; 0929-8673
    ISSN (online) 1875-533X
    ISSN 0929-8673
    DOI 10.2174/0929867330666230523155739
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Effects of Donepezil and Medroxyprogesterone Versus Placebo on Weaning in Adult Patients With Non-Pulmonary Etiologies Receiving Invasive Mechanical Ventilation: A triple-blind Randomized Clinical Trial.

    Alizadeh, Zahra / Sahebnasagh, Adeleh / Hadadzadegan, Navid / Mohammadi, Farhad / Saghafi, Fatemeh

    Frontiers in pharmacology

    2021  Volume 12, Page(s) 735594

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2021-12-06
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2021.735594
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Therapeutic Role of HAT Therapy in Sepsis: A Systematic Review and Meta-Analysis.

    Saghafi, Fatemeh / Boostani Moghadam, Zahra / Salehi-Abargouei, Amin / Beigrezaei, Sara / Sohrevardi, Seyed Mojtaba / Jamialahmadi, Tannaz / Sahebnasagh, Adeleh / Sahebkar, Amirhossein

    Current medicinal chemistry

    2024  

    Abstract: Background: This systematic review and meta-analysis aimed to determine whether the combination of hydrocortisone, vitamin C (ascorbic acid), and thiamine (HAT therapy) diminishes the mortality and is effective in expediting the resolution of sepsis and ...

    Abstract Background: This systematic review and meta-analysis aimed to determine whether the combination of hydrocortisone, vitamin C (ascorbic acid), and thiamine (HAT therapy) diminishes the mortality and is effective in expediting the resolution of sepsis and septic shock or not.
    Methods: The following databases of PubMed, Scopus, ISI Web of Science, and Google Scholar were explored until March 2021 for all existing literature related to this field. An automatic alert for all databases was also activated to update our search. Meta-analysis was performed on clinical trials and cohorts separately as well as on all the pooled populations.
    Results: This study evaluated nine clinical trials (1358 participants) and nine cohorts (339,437 participants) and is the most comprehensive systematic review in this field. The results of our meta-analysis demonstrated a significant difference in the reduction of Sepsis-Related Organ Failure Assessment (SOFA) score changes (Δ-SOFA) over 72 h (Standard Mean Difference (SMD) = -0.429; 95% CI: -0.737, 0.120; P = 0.006), duration of vasopressor (VP) (SMD = -0.373; 95% CI: -0.619, -0.128; P = 0.003), and procalcitonin (PCT) clearance (SMD = 0.496; 95% CI: 0.061, 0.931%; P = 0.026). Considering the results of cohorts, HAT therapy was effective in the survival of intensive care units (ICUs) patients (OR = 0.641; 95% CI: 0.423-0.970, P = 0.035). However, no significant difference was observed between the intervention and control groups in hospital mortality (Odds Ratio (OR) = 0.811, 95% CI: 0.544-1.209, P = 0.304), 28- to 30-day mortality (OR = 1.000; 95% CI: 0.782-1.279, P = 0.998), new onset acute kidney injury requiring renal replacement therapy ((OR = 0.856, 95% CI: 0.526, 1.391; P = 0.529), in-hospital length of stay (LOS) (SMD = 0.090; 95% CI: -0.036, 0.216 days; P = 0.162), LOS in ICU (SMD = 0.016, 95% CI: -0.138, 0.170 days; P = 0.838), and mechanical ventilation-free days (SMD = 0.004; 95% CI: -0.154, 0.163 days; P = 0.956).
    Conclusion: Supplementation of septic and septic shock patients with HAT therapy has significant beneficial effects on SOFA score over 72 hours, duration of exogenous vasopressor infusion and procalcitonin clearance. Considering the results of cohort studies, supplementation with HAT is efficacious in reducing ICU mortality.
    Language English
    Publishing date 2024-01-22
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 1319315-6
    ISSN 1875-533X ; 0929-8673
    ISSN (online) 1875-533X
    ISSN 0929-8673
    DOI 10.2174/0109298673245464231121094448
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Prevention of radiotherapy-related oral mucositis with zinc and polyherbal mouthwash: a double-blind, randomized clinical trial.

    Sahebnasagh, Marzieh / Aksi, Vahideh / Eslami, Fatemeh / Lashkardoost, Hossein / Kasaian, Jamal / Golmohammadzadeh, Shiva / Parkam, Bahareh / Negarandeh, Reza / Saghafi, Fatemeh / Sahebnasagh, Adeleh

    European journal of medical research

    2023  Volume 28, Issue 1, Page(s) 109

    Abstract: Background: A significant percentage of head and neck cancer (HNCs) patients receiving RT experience oral mucositis (OM). This study aimed to evaluate the effect of the polyherbal (containing chamomile, peppermint oil, Aloe vera, and honey) and zinc ... ...

    Abstract Background: A significant percentage of head and neck cancer (HNCs) patients receiving RT experience oral mucositis (OM). This study aimed to evaluate the effect of the polyherbal (containing chamomile, peppermint oil, Aloe vera, and honey) and zinc mouthwashes in comparison to the control (chlorhexidine) and placebo groups for prevention of radiation-induced OM.
    Methods: This study was a double-blinded randomized clinical trial, conducted on 67 patients with HNCs undergoing radiotherapy. The eligible participants were randomized to receive either one of the following; zinc sulfate, polyherbal, chlorhexidine (Vi-one 0.2% CHX), or placebo mouthwash for 6 weeks. Follow-up evaluation of oral hygiene and the checklists of OM and the intensity of pain were filled out according to WHO assessment tool, Oral Mucositis Assessment Scale (OMAS), and Visual Analog Scale (VAS) in all the participants weekly for seven consecutive weeks.
    Results: The results of present clinical trial demonstrated that the use of either zinc sulfate or polyherbal mouthwash significantly reduced the scores of OM and the severity of pain during weeks 2 to 7 after consumption compared with the CHX or placebo mouthwashes (P < 0.05). According to the post hoc analysis and compared with the placebo, a significantly better result was reported for zinc sulfate and polyherbal mouthwashes at weeks 2 to 7, but not for the CHX mouthwash.
    Conclusion: This study showed that the use of zinc sulfate or polyherbal mouthwashes is effective in prevention of both OM severity scores and pain related to OM intensity at weeks 2 to 7 following consumption in HNCs patients. Trial registration IRCT20190123042475N1 and IRCT20190123042475N2. Registration date: 2019-06-09, 2019-07-26.
    MeSH term(s) Humans ; Mouthwashes/therapeutic use ; Zinc/therapeutic use ; Zinc Sulfate/therapeutic use ; Chlorhexidine ; Stomatitis/drug therapy ; Stomatitis/etiology ; Stomatitis/prevention & control
    Chemical Substances Mouthwashes ; Zinc (J41CSQ7QDS) ; Zinc Sulfate (7733-02-0) ; Chlorhexidine (R4KO0DY52L)
    Language English
    Publishing date 2023-03-02
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 1329381-3
    ISSN 2047-783X ; 0949-2321
    ISSN (online) 2047-783X
    ISSN 0949-2321
    DOI 10.1186/s40001-023-01015-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Neurohormetic phytochemicals in the pathogenesis of neurodegenerative diseases.

    Sahebnasagh, Adeleh / Eghbali, Samira / Saghafi, Fatemeh / Sureda, Antoni / Avan, Razieh

    Immunity & ageing : I & A

    2022  Volume 19, Issue 1, Page(s) 36

    Abstract: The world population is progressively ageing, assuming an enormous social and health challenge. As the world ages, neurodegenerative diseases are on the rise. Regarding the progressive nature of these diseases, none of the neurodegenerative diseases are ... ...

    Abstract The world population is progressively ageing, assuming an enormous social and health challenge. As the world ages, neurodegenerative diseases are on the rise. Regarding the progressive nature of these diseases, none of the neurodegenerative diseases are curable at date, and the existing treatments can only help relieve the symptoms or slow the progression. Recently, hormesis has increased attention in the treatment of age-related neurodegenerative diseases. The concept of hormesis refers to a biphasic dose-response phenomenon, where low levels of the drug or stress exert protective of beneficial effects and high doses deleterious or toxic effects. Neurohormesis, as the adaptive aspect of hormetic dose responses in neurons, has been shown to slow the onset of neurodegenerative diseases and reduce the damages caused by aging, stroke, and traumatic brain injury. Hormesis was also observed to modulate anxiety, stress, pain, and the severity of seizure. Thus, neurohormesis can be considered as a potentially innovative approach in the treatment of neurodegenerative and other neurologic disorders. Herbal medicinal products and supplements are often considered health resources with many applications. The hormesis phenomenon in medicinal plants is valuable and several studies have shown that hormetic mechanisms of bioactive compounds can prevent or ameliorate the neurodegenerative pathogenesis in animal models of Alzheimer's and Parkinson's diseases. Moreover, the hormesis activity of phytochemicals has been evaluated in other neurological disorders such as Autism and Huntington's disease. In this review, the neurohormetic dose-response concept and the possible underlying neuroprotection mechanisms are discussed. Different neurohormetic phytochemicals used for the better management of neurodegenerative diseases, the rationale for using them, and the key findings of their studies are also reviewed.
    Language English
    Publishing date 2022-08-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2168941-6
    ISSN 1742-4933
    ISSN 1742-4933
    DOI 10.1186/s12979-022-00292-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials.

    Saghafi, Fatemeh / Bagheri, Negar / Salehi-Abargouei, Amin / Sahebnasagh, Adeleh

    Journal of intensive care

    2022  Volume 10, Issue 1, Page(s) 5

    Abstract: Background: This study investigated whether combination therapy with vasopressin, steroid, and epinephrine (VSE) improves in-hospital survival and return of spontaneous circulation (ROSC) during and after resuscitation in-hospital cardiac arrest (CA).!## ...

    Abstract Background: This study investigated whether combination therapy with vasopressin, steroid, and epinephrine (VSE) improves in-hospital survival and return of spontaneous circulation (ROSC) during and after resuscitation in-hospital cardiac arrest (CA).
    Materials and methods: Various databases were explored from inception until October 2021 for relevant published clinical trials and cohort studies.
    Results: Three clinical trials were included. Pooled analysis suggested that VSE was significantly associated with increased ROSC in patients with in-hospital CA (IHCA) (odds ratio (OR): 2.281, 95% confidence interval (CI): 1.304-3.989, P value = 0.004). Meta-analysis of two studies (368 patients) demonstrated a significant difference in the reduction of mean arterial pressure (MAP) during and 15-20 min after cardiopulmonary resuscitation (standardized mean difference (SMD): 1.069, 95% CI: 0.851-1.288, P value < 0.001), renal failure free days (SMD = 0.590; 95% CI: 0.312-0.869 days; P value < 0.001), and coagulation failure free days (SMD = 0.403; 95% CI: 0.128-0.679, P value = 0.004). However, no significant difference was observed for survival-to-discharge ratio (OR: 2.082, 95% CI: 0.638-6.796, P value = 0.225) and ventilator free days (SMD = 0.201, 95% CI: - 0.677, 1.079 days; P value = 0.838).
    Conclusions: VSE combination therapy during and after IHCA may have beneficial effects in terms of the ROSC, renal and circulatory failure free days, and MAP. Prospero registration: CRD42020178297 (05/07/2020).
    Language English
    Publishing date 2022-02-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2739853-5
    ISSN 2052-0492
    ISSN 2052-0492
    DOI 10.1186/s40560-022-00597-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The preventive effect of the combination of atorvastatin and nortriptyline in migraine-type headache: a randomized, triple-blind, placebo-controlled trial.

    Sherafat, Amir / Sahebnasagh, Adeleh / Rahmany, Roya / Mohammadi, Farhad / Saghafi, Fatemeh

    Neurological research

    2022  Volume 44, Issue 4, Page(s) 311–317

    Abstract: Background and purpose: Migraine ranked as the eighth cause of disability worldwide. Statins with anti-inflammatory and vasodilatory endothelial effects have been introduced as an option for the prevention of migraine-type headaches. The current study ... ...

    Abstract Background and purpose: Migraine ranked as the eighth cause of disability worldwide. Statins with anti-inflammatory and vasodilatory endothelial effects have been introduced as an option for the prevention of migraine-type headaches. The current study aimed to assess the efficacy and tolerability of atorvastatin for the prevention of migraine in adults.
    Method: This prospective, triple-blind, randomized controlled clinical trial was performed in adult migraineurs from mid-July 2019 to late-April 2020. Patients were randomly assigned to receive atorvastatin or placebo in combination with nortriptyline for 24-weeks. The frequency of headache was the primary outcome, and intensity of the headache and quality of life (QOL) were the secondary outcomes for this study.
    Results: With 34 patients in each arm, 68 patients with migraines based on the International Headache Society (IHS) criteria were enrolled in the study. At week 24, patients in the atorvastatin group experienced significantly fewer migraine attacks than the placebo group (P-value = 0.004). Moreover, there were significant differences between the two groups in QOL at follow-up intervals of 14 (P-value = 0.001) and 24 (P-value < 0.001) weeks. However, no significant difference was observed in the intensity of headache was observed in both groups (P-value > 0.05). The most common adverse effects in intervention and control groups were constipation and insomnia, respectively.
    Conclusion: In patients with migraine, prophylaxis with atorvastatin significantly improved the frequency of headache and QOL over 24 weeks compared with placebo with no effect on the intensity of headache. Statins seem to be a potential promising drug for prophylaxis of migraine headaches.
    MeSH term(s) Adrenergic Uptake Inhibitors/pharmacology ; Adult ; Atorvastatin/adverse effects ; Atorvastatin/pharmacology ; Constipation/chemically induced ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Male ; Middle Aged ; Migraine Disorders/prevention & control ; Nortriptyline/pharmacology ; Outcome Assessment, Health Care ; Sleep Initiation and Maintenance Disorders/chemically induced
    Chemical Substances Adrenergic Uptake Inhibitors ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Atorvastatin (A0JWA85V8F) ; Nortriptyline (BL03SY4LXB)
    Language English
    Publishing date 2022-01-17
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 424428-x
    ISSN 1743-1328 ; 0161-6412
    ISSN (online) 1743-1328
    ISSN 0161-6412
    DOI 10.1080/01616412.2021.1981105
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.

    Mohammadi, Farhad / Harofteh, Fatemeh Zare / Sahebnasagh, Adeleh / Ghaneei, Narges / Ardakani, Mohammad Ebrahim Zadeh / Saghafi, Fatemeh

    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)

    2023  Volume 30, Issue 4, Page(s) e13689

    Abstract: Background: Considering the pathogenesis of psoriasis and also the anti-oxidant, immunomodulatory, and anti-inflammatory properties of rosuvastatin and melatonin, the current clinical trial aimed to evaluate the efficacy of topical rosuvastatin and ... ...

    Abstract Background: Considering the pathogenesis of psoriasis and also the anti-oxidant, immunomodulatory, and anti-inflammatory properties of rosuvastatin and melatonin, the current clinical trial aimed to evaluate the efficacy of topical rosuvastatin and melatonin in patients with mild to moderate psoriasis.
    Methods: The current randomized placebo-controlled clinical trial was conducted using a 3-arm parallel group included 77 adult patients (≥18 years old) with mild to moderate plaque psoriasis. Patients were randomized into a 1:1:1 ratio to one of three groups to receive one of the three interventions: melatonin cream, 5.0% (w/w), rosuvastatin cream, 5.0% (w/w), or placebo cream with a similar transparent appearance twice a day for 12 weeks. The primary outcome was severity of the disease using Psoriasis Area Severity Index (PASI). The secondary outcomes included the Dermatological Sum Score (DSS) to assess the erythema, scaling, and plaque elevation and the Dermatology Life Quality Index (DLQI). Photographs of the lesions were also taken at the baseline and at different periodic intervals thereafter.
    Results: Among 77 randomized patients, 52 (mean (SD) age, 40.67 (10.85) years; 22 (42.30%) men) completed the study. A significant reduction of 45% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 70% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 46% (mean (SD) of 2.91(1.85) to 1.57 (1.11)) and 77% (mean (SD) of 2.91 (1.85) to 0.87 (0.67)) in DSS score on days 30 and 60 with rosuvastatin cream, 5% w/w (P < 0.001) compared with baseline was observed, respectively. Also a significant decrease of 35% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 51% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 40% (mean (SD) of 5.00 (1.58) to 3.00 (1.76))and 61% (mean (SD) of 5.00 (1.58) to 1.92 (1.71)) in DSS score on days 30 and 60 with melatonin cream, 5% w/w (P < 0.001) compared with baseline were observed, respectively. In each of the melatonin or rosuvastatin groups, DLQI improved significantly on days 30 (P < 0.0001) and 60 (P < 0.001) while the changes in the control group were not significant.
    Conclusion: The results of this clinical trial demonstrated that topical melatonin and rosuvastatin diminished the severity of mild to moderate plaque psoriasis with a satisfactory safety profile. Future clinical trials should assess both the long-term efficacy and safety of melatonin and rosuvastatin creams in larger study populations.
    MeSH term(s) Adult ; Male ; Humans ; Adolescent ; Female ; Melatonin/adverse effects ; Rosuvastatin Calcium/adverse effects ; Psoriasis/drug therapy ; Psoriasis/pathology ; Anti-Inflammatory Agents ; Treatment Outcome ; Severity of Illness Index ; Double-Blind Method
    Chemical Substances Melatonin (JL5DK93RCL) ; Rosuvastatin Calcium (83MVU38M7Q) ; Anti-Inflammatory Agents
    Language English
    Publishing date 2023-12-26
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 1229160-2
    ISSN 1600-0846 ; 0909-752X ; 1397-1344
    ISSN (online) 1600-0846
    ISSN 0909-752X ; 1397-1344
    DOI 10.1111/srt.13689
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top